296 RASolve 301 Trial in Progress: A Phase 3 Study of Daraxonrasib (RMC-6236) vs. Docetaxel in Patients with Previously Treated RAS-Mutant Non-Small Cell Lung Cancer (NSCLC)
作者
Colin R. Lindsay,Ferdinandos Skoulidis,Kathryn Cecilia Arbour,Hidehito Hironouchi,Gérard Zalcman,Alessandra Curioni Fontecedro,Jarushka Naidoo,Adrianus Johannes de Langen,Lin Tao,Erica Su,Minoti Hiremath,Achim Rittmeyer,Melissa Johnson,Sanjay Popat
出处
期刊:Lung Cancer [Elsevier BV] 日期:2026-02-01卷期号:212: 109244-109244